Drug intelligence / Profile preview

vorasidenib + pembrolizumab

Development stage: Unknown
Lead developer: Servier Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Vorasidenib plus pembrolizumab is an investigational combination therapy being developed by Servier for the treatment of IDH-mutant gliomas. Vorasidenib is an orally available, brain-penetrant small molecule inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance T-cell anti-tumor activity. The rationale for the combination is to leverage the metabolic and epigenetic modulation of the tumor microenvironment by IDH inhibition to potentially sensitize the glioma to PD-1 blockade. It is currently being evaluated in a Phase 1 clinical trial (NCT05484622) for patients with recurrent or progressive IDH1-mutant astrocytomas and oligodendrogliomas.

Other names: vorasidenib plus pembrolizumab

Targets

IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)PDCD1 (Programmed cell death protein 1 receptor)IDH2 (Isocitrate dehydrogenase [NADP], mitochondrial (mutant))

Beyond the preview

Go deeper on vorasidenib + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vorasidenib + pembrolizumab.

Explore the full profile